Literature DB >> 1277182

Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine.

M Aoshima, S Tsukagoshi, Y Sakurai, J Oh-ishi, T Ishida.   

Abstract

New derivatives of 1-beta-D-arabinofuranosylcytosine were synthesized and their antitumor activities were tested against mouse leukemia L1210. Among the 50 compounds investigated, a series of N4-acyl derivatives with long-chain saturated fatty acids were found to be highly active. The most active derivatives were N4-stearoly-1-beta-D-arabinofuranosylcytosine, which was administered in the form of suspension, and N4-behenoyl-1-beta-D-arabinofuranosylcytosine given in the form of solution. They were superior to the parent compound, 1-beta-D-arabinofuranosylcytosine, in that smaller dosages exhibited strong activities regardless of the treatment schedule, and they were also resistant to cytidine deaminase.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277182

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Clinical pharmacokinetics of cytarabine formulations.

Authors:  Akinobu Hamada; Takeo Kawaguchi; Masahiro Nakano
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.

Authors:  E Nagura; K Kimura; K Yamada; K Ohta; T Maekawa; F Takaku; H Uchino; T Masaoka; I Amaki; K Kawashima
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Ubenimex in the treatment of acute nonlymphocytic leukemia in adults.

Authors:  A Urabe; Y Mutoh; H Mizoguchi; F Takaku; N Ogawa
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

5.  Phase I clinical and pharmacokinetic study of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.

Authors:  R Ohno; K Kimura; K Ota; Y Miura; A Hoshino; K Hattori; M Hirano; M Ito; T Maekawa; T Nakamura
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

6.  Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.

Authors:  K Kimura; R Ohno; I Amaki; K Hattori; Y Hirota; A Hoshino; M Ichimaru; M Ito; I Kimura; T Maekawa
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

7.  Treatment of leukemia and myelodysplastic syndromes with orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.

Authors:  R Ohno; M Hirano; K Yamagata; K Ohara; S Shirakawa; Y Hirota; M Kobayashi; S Yoshikawa; Y Mitomo; Y Ikeda
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 8.  Improving nucleoside analogs via lipid conjugation: Is fatter any better?

Authors:  Peter Alexander; Gregory Kucera; Timothy S Pardee
Journal:  Crit Rev Oncol Hematol       Date:  2016-01-21       Impact factor: 6.312

9.  Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.

Authors:  T Ueda; T Nakamura; D Kagawa; M Uchida; N Domae; M Sugiyama; Y Ueda; M Sasada; H Uchino
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.

Authors:  Dae Hyoung Lee; Nak Gyun Chung; Bin Cho; Hack Ki Kim; Hyoung Jin Kang; Hee Young Shin; Hyo Seop Ahn; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Hoon Kook; Tai Ju Hwang; Ho Joon Im; Jong Jin Seo; Hyeon Jin Park
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.